leadership
confidence high
sentiment neutral
materiality 0.50
Nexalin SVP Quality/Regulatory/Clinical Carolyn Shelton departs; separation terms set
Nexalin Technology, Inc.
- Carolyn Shelton departed as SVP of Quality, Regulatory, and Clinical Affairs on Aug 28, 2026.
- Separation agreement includes one month of base salary and a $20,000 2026 bonus.
- Unvested stock options accelerated; vested options exercisable for up to two years.
- Health insurance premiums subsidized through Sept 30, 2026; includes release of claims and confidentiality/non-disparagement/cooperation.
- Agreement to be filed as exhibit to next periodic report.